Results 211 to 220 of about 593,183 (294)

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić   +7 more
wiley   +1 more source

Separating selection from mutation in antibody language models. [PDF]

open access: yesElife
Matsen FA   +8 more
europepmc   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman   +9 more
wiley   +1 more source

High Yield Branched Puromycin Linker Design Enables Efficient cDNA Display and Chemical Modification of Peptides

open access: yesBiotechnology and Bioengineering, EarlyView.
A novel puromycin linker for cDNA display was synthesized via SPAAC reaction. Its functionality was confirmed by recovering intact DNA after selection against EpCAM. The system also enabled the verification of bicyclic peptides during display, demonstrating its utility for constructing and screening structurally complex peptide libraries.
Simon Schneider   +3 more
wiley   +1 more source

Codon usage bias and selective constraints in Gentianales mitogenomes. [PDF]

open access: yesBMC Genomics
Amenu SG   +5 more
europepmc   +1 more source

All You Can Eat Yeast: Substituting Hexose Transporters With AtSWEET7 Alleviates Glucose Repression, Enabling Simultaneous Utilization of Sugars in Renewable Feedstocks

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Yeast sugar transporters have highly evolved for preferential glucose transport, a significant roadblock for utilizing non‐glucose sugars in renewable feedstocks such as lignocellulosic biomass. To enable simultaneous transport of multiple sugars, native hexose transporters were replaced by SWEET7p from Arabidopsis thaliana in engineered ...
Nurzhan Kuanyshev   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy